CMS CAMERON MCKENNA NABARRO OLSWANG LLP
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Theatrical Producers (Except Motion Picture) and Miscellaneous Theatrical Services, Health and Allied Services, Not Elsewhere Classified, Legal Services, Individual and Family Social Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about CMS CAMERON MCKENNA NABARRO OLSWANG LLP
Live alerts from global media, monitored by Business Radar
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-12-16 (businesswire.com)
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance | Business Wire
Amentum Holdings, Inc. (“Amentum” or the “Company”) (NYSE: AMTM), a leading advanced engineering and technology company, today announced results for t
Read more
2024-10-25 (beckershospitalreview.com)
213 CNOS to know | 2024
Becker's is thrilled to honor healthcare CNOs. Chief nursing officers are responsible for tackling nurse staffing shortages, managing nursing budgets and more.
Read more
2023-12-20 (scottishlegal.com)
CMS announces law scholarships for Scottish pupils
CMS has announced it will offer scholarships to support three Scottish pupils in pursuing their dream of a legal career. As part of an annual UK-wide initiative, the CMS Law Scholarships Scheme for Scotland awards £2,500 each year to high-performing state school students from economically chal
Read more
2023-12-06 (thelawyer.com)
Skadden and Linklaters lead on sale of KFC restaurants
Skadden Arps Slate Meagher & Flom and Linklaters are the two firms that have won roles on the sale of KFC’s 218 restaurants in the UK by EG Group to Yum! brands’ KFC division. Skadden fielded a team...
Read more
2023-11-07 (thelawyer.com)
Pallas Partners loses first partner as ClientEarth lawyer departs
Litigation boutique Pallas Partners has lost its first partner since its launch in February 2022. Will Hooker, who has been representing ClientEarth in its climate litigation against Shell...
Read more
2023-05-29 (finsmes.com)
Amplo Biotechnology Receives Fast Track Phase I/II STTR Grant from NIH-NIAMS
Amplo Biotechnology, a San Diego, CA-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular junction disorders, announced the award of a Fast Track Phase I/II STTR grant from the NIH-NIAMS
Read more